Strand Therapeutics
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $198M
Overview
A pioneer in programmable mRNA therapeutics for oncology and immunology applications.
OncologyImmunology
Technology Platform
A platform for designing logic-gated, programmable mRNA therapeutics that activate specifically in diseased tissues to improve safety and efficacy.
Funding History
2Total raised:$198M
PIPE$153M
Series A$45M
Opportunities
The proven success of mRNA vaccines validates the modality, creating investor and partner interest for next-generation, targeted applications.
Risk Factors
Unproven clinical efficacy of complex programmable mRNA in humans and potential manufacturing challenges for these sophisticated constructs.
Competitive Landscape
A frontrunner in programmable mRNA, competing with other logic-gated RNA firms and traditional mRNA companies expanding into therapeutics.